4:16 PM ET
8-K
Investor Presentation
Keros Therapeutics Investor Presentation
Keros Therapeutics updated its corporate presentation for use in meetings with investors and analysts. The presentation highlights the company's clinical pipeline, including rinvatercept (KER-065) for Duchenne muscular dystrophy and ALS, and elritercept for myelodysplastic syndromes.